Vablys®
Dequalinium chloride tablets
Available For Your Patients With Bacterial Vaginosis1
Vablys® (dequalinium chloride) is indicated for the treatment of bacterial vaginosis in adult women under 55 years of age. Other pathogens commonly associated with vulvovaginitis such as Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, Candida albicans and Herpes simplex virus should be ruled out.
No data are available to Health Canada in children < 18 years of age or women > 55 years of age; therefore, Health Canada has not authorized an indication in these populations.
Sign up to receive emails from Duchesnay about Vablys® tools and events
Click here for additional safety information and for a link to the Product Monograph discussing:
- Contraindications in patients who are hypersensitive to the drug or to any ingredient in the formulation, or component of the applicator, patients with ulceration of the vaginal epithelium and the vaginal portion of the cervix, and premenarchal patients.
- Relevant warnings and precautions regarding vaginal use only, re-treatment of patients who failed or immediately relapsed on Vablys®, intravaginal use of anionic substances (i.e. soaps), increased dose and treatment duration, fertility, pregnancy, and delivery of newborn.
- Adverse reactions in patient who received Vablys® including vaginal discharge, vulvovaginal pruritus, vulvovaginal candidiasis, vulvovaginal burning sensation and bacterial vulvovaginitis.
- Conditions of clinical use, adverse reactions, dosing instructions and drug interactions.